STOCK TITAN

[SCHEDULE 13G/A] Relay Therapeutics, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Commodore Capital and related filers reported beneficial ownership of 13,350,000 shares of Relay Therapeutics (RLAY), representing 7.8% of the outstanding common stock as of June 30, 2025. The Schedule 13G/A names Commodore Capital LP, Commodore Capital Master LP, and managing partners Michael Kramarz and Robert Egen Atkinson as joint filers. The Firm acts as investment manager to Commodore Capital Master LP and the managing partners exercise investment discretion. The filing states the position was not acquired to change or influence control and attaches a Joint Filing Agreement.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Commodore reports a meaningful passive stake in RLAY (7.8%) under Schedule 13G/A; disclosure is routine but material for holders.

The filing discloses a non-control, passive aggregate stake of 13,350,000 shares (7.8%) in Relay Therapeutics as of June 30, 2025. This is a standard Section 13 reporting form indicating shared voting and dispositive power among the filers and clarifies the investment manager relationship. For investors, the filing provides transparency on a sizeable holder but does not indicate an activist intent or control transaction.

TL;DR: Joint filing shows coordinated ownership and voting/dispositive sharing but affirms no purpose to change control.

The Schedule 13G/A lists joint filing parties and specifies shared voting and dispositive power over the 13.35M shares. The certification states the holdings were not acquired to influence control, consistent with a passive investor filing. The presence of a Joint Filing Agreement and signatures from managing partners confirms coordination in reporting, which is important for governance disclosure even if no control intent is claimed.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Commodore Capital LP
Signature:Michael Kramarz
Name/Title:Managing Partner
Date:08/14/2025
Commodore Capital Master LP
Signature:Michael Kramarz
Name/Title:Authorized Signatory
Date:08/14/2025
Robert Egen Atkinson
Signature:Robert Egen Atkinson
Name/Title:Authorized Signatory
Date:08/14/2025
Michael Kramarz
Signature:Michael Kramarz
Name/Title:Authorized Signatory
Date:08/14/2025
Exhibit Information

Exhibit 1: Joint Filing Agreement

Relay Therapeutics, Inc.

NASDAQ:RLAY

RLAY Rankings

RLAY Latest News

RLAY Latest SEC Filings

RLAY Stock Data

1.50B
142.09M
1.42%
100.37%
13.18%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
CAMBRIDGE